Toronto, ON – September 27, 2018
GreenSky Capital Inc. is very pleased to welcome Dr. Vincent Lenaerts as the new Chief Executive Officer of Nanovista Inc. (“Nanovista”).
Dr. Lenaerts has executive experience in a variety of fields including nanotechnologies, drug delivery, diagnostics, peptides, endocrinology, ophthalmology and oncology and has held CEO positions at Miraculins, Bioxalis Medica and Apidel in Switzerland. Dr. Lenaerts has a Bachelor of Pharmacy, a Master of Science in Industrial Pharmacy and a Ph.D. in Pharmaceutical Sciences from the University of Louvain. In 1999, he was recognized with the Joseph-Armand Bombardier Award for Technological Innovation, awarded by the ACFAS.
Dr. Lenaerts has a successful track record of leading early stage high-growth biopharmaceutical companies, including expertise in managing the regulatory and capital raising processes. “I am quite excited to join one of the Ten Start-Ups Changing Healthcare as selected by Scientific American in 2017,” said Dr. Lenaerts. “There is a real need for safer cancer surgeries resulting in complete removal of malignant tissues. For many patients, Nanovista’s technology could obviate the need to administer chemotherapy or radiotherapy.”
Dr. Christine Allen, President of Nanovista, says “My co-founders and I are delighted to have Dr. Lenaerts join Nanovista as CEO. Vincent brings a depth and breadth of experience building successful companies. His leadership will help Nanovista realize the full potential of its technology platform.”
About Nanovista Inc.
Nanovista’s multimodal visualization agents are designed to improve the performance of image-guided cancer therapy as a critical tool within precision medicine. For further information, please visit www.nanovista.ca.
About GreenSky Capital Inc.
GreenSky Capital Inc. makes investments in early-stage Canadian technology companies through its affiliated venture capital funds, GreenSky Accelerator Fund I, LP and GreenSky Accelerator Fund II, LP. GreenSky principals bring a unique combination of experience in technology, law and finance to high-growth potential companies and dedicated entrepreneurs. For more information, please visit www.greenskycapital.com.
Early-stage Canadian technology companies interested in working with Fund II are invited to learn more about, and apply to, the GreenSky Accelerator Funds at: email@example.com or by visiting the website at https://www.greenskycapital.com/entrepreneurs/#application.